Updated version of this database is available at ThpDB2

Detailed description page of THPdb

This page displays user query in tabular form.

1159 details
Primary information
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameHemofil M
CompanyN.A.
Brand DiscriptionHemofil M is a human clotting factor derived from pooled human plasma. It works by increasing the amount of clotting factor VII in the blood, helping the blood form clots and stop bleeding
Prescribed forPreventing and controlling bleeding in patients with hemophilia A, including in surgical settings.
Chemical NameN.A.
FormulationHEMOFIL is available as single dose bottles that contain nominally 250 (NDC 0944-2930-01), 500 (NDC 0944-2931-01), 1000 (NDC 0944-2932-01), and 1700 (NDC 0944-2933-01) IU per bottle. Each bottle is labeled with the potency in International Units, and is p
Physcial AppearnceDry concentrate
Route of AdministrationIntravenous Injection
Recommended DosageThe expected in vivo peak AHF level, expressed as IU/dL of plasma or percent of normal, can be calculated by multiplying the dose administered per kg body weight (IU/kg) by two.
ContraindicationAllergic
Side EffectsRash; hives; itching; difficulty breathing; flushing; tightness in the chest; swelling of the mouth, face, lips, or tongue; wheezing; chest pain; fainting; nausea; severe or persistent dizziness or light-headedness; shortness of breath.
Useful Linkhttp://www.drugs.com/cdi/hemofil-m.html
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)